Autism Spectrum Disorders including autism and Asperger disorder
Conditions
Interventions
Intervention type:DRUG
Name of intervention:Aravita
Dose form / Japanese Medical Device Nomenclature:CAPSULE
Route of administration / Site of application:ORAL
Dose per administration:240
mg
Dosing fr
Sponsors
Kunio Yui
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 13 individuals who met DSM-IV-R criteria for high functioning autistic disorder or Asperger's Disorder, corroborated by the Autism Diagnostic Interview-Revised. Participants were free of any medical or comorbid psychiatric disorders. Other inclusion criteria included either a verbal or performance intelligence quotient above 80, and a score greater than 10 on the social withdrawal subscale of the Aberrant Behavior Checklist-Community (ABC)
Exclusion criteria
Exclusion criteria: Subjects who have total intelligence quotient is 79 or under score, lower than 10 of ABC-C social withdrawal subscale score, and medical treatment or taking other drugs due to other psychiatric disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Abberant Behavior Cheklist-community (ABC-C),Social Responsiveness Scale (SRS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Social Interaction and repetitive, stereotyped pattern of behavior and interest subscales of Autism Diagnostic Interview-revised (ADI-R) | — |
Countries
Japan
Contacts
Public ContactKazuhiko Saito
Pharmacological management office of the SAWA hospital
Outcome results
None listed